Aquestive Therapeutics said it remains on track to resubmit the NDA for Anaphylm, its epinephrine sublingual film for severe allergic reactions, in Q3 2026. The company also reported higher first-quarter revenue and a narrower net loss, signaling improving operating performance. The update is positive but still largely clinical/regulatory execution-dependent.
Aquestive Therapeutics said it remains on track to resubmit the NDA for Anaphylm, its epinephrine sublingual film for severe allergic reactions, in Q3 2026. The company also reported higher first-quarter revenue and a narrower net loss, signaling improving operating performance. The update is positive but still largely clinical/regulatory execution-dependent.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
mildly positive
Sentiment Score
0.18
Ticker Sentiment
